Plain-English translation of NCT06815939 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new screening tool called Automated Visual Evaluation (AVE), which uses artificial intelligence to analyze images of the cervix and detect early signs of cervical cancer. The study will compare how well this new tool works compared to standard cervical cancer screening methods like HPV testing and visual inspection. The research involves 10,000 women in El Salvador and aims to make cervical cancer screening faster, cheaper, and more accessible in communities that don't have easy access to traditional laboratory testing.
Cervical cancer caused by human papillomavirus (HPV) is a major health problem in lower-income countries, where most deaths from this cancer occur. Many women in these areas can't access standard screening and treatment because of cost and lack of medical resources. This trial exists to validate a new, low-cost tool that could bring effective cervical cancer screening to women who need it most.
You likely qualify if…
You likely don't qualify if…
You would attend three visits over several weeks. At your first screening visit, you'll provide an HPV sample, undergo visual inspection with a special solution, and have digital images taken of your cervix using the new AVE tool. Depending on your screening results, you may be referred to a follow-up colposcopy visit (a closer examination of the cervix) where a small tissue sample may be taken if needed. If any precancerous changes are found, you'll receive treatment following standard care practices in El Salvador.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
El Salvador